: GSK says it disagrees with California state court ruling on Zantac


U.K. pharmaceutical giant GSK on Friday said it disagreed with a California state court ruling on Zantac, or ranitidine, and its links with cancer. “Following the 13 epidemiological studies conducted looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer,” the pharmaceutical said. It added the decision relates only to the question of whether the plaintiff’s experts can testify at trial. “It does not mean that the Court agrees with plaintiff’s experts’ scientific conclusions or their litigation-driven science,” the company said. GSK GSK, -2.55% shares fell 4% in London.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleNerdWallet: On ‘hush trips,’ employees sneak off to vacation spots to work remotely. Is that so bad?
Next article: ‘We do not do the end of life well’ in America: How hospice can help ease the last days


Please enter your comment!
Please enter your name here